Local cell therapy using CCL19-expressing allogeneic mesenchymal stem cells exerts robust antitumor effects by accumulating CD103 + IL-12-producing dendritic cells and priming CD8 + T cells without involving draining lymph nodes
Journal for ImmunoTherapy of Cancer · 2024
DOI: 10.1136/jitc-2024-009683 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2024. Verfasst von Yuichi Iida und 1 weiteren Autor:innen. Beteiligte Einrichtung: Immunology, Shimane University Faculty of Medicine Graduate School of Medicine, Izumo, Japan yiida@med.shimane-u.ac.jp. Hauptthemen laut MEDLINE: Chemokine CCL19, Dendritic Cells, Mesenchymal Stem Cells, CD8-Positive T-Lymphocytes. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Background
Immune checkpoint blockade is a promising anticancer therapy, whereas the presence of T cells in tumor sites is indispensable for its therapeutic efficacy. To promote the infiltration of T cells and dendritic cells (DCs) into the tumor, we previously proposed a local cell therapy using chemokine (C-C motif) ligand 19 (CCL19)-expressing immortalized syngeneic immortalized mesenchymal stem cells (syn-iMSC/CCL19). However, the preparation of syngeneic/autologous MSC from individual hosts limits the clinical application of this cell therapy.
Methods
In this study, we further developed a new cell therapy using allogeneic iMSC/CCL19 (allo-iMSC/CCL19) using several tumor mice models.
Results
The allo-iMSC/CCL19 therapy exerted drastic antitumor effects, in which the host’s T cells were induced to respond to allogeneic MSC. In addition, the allo-iMSC/CCL19 therapy promoted the infiltration of CD103 + interleukin (IL)-12-producing DCs and priming of CD8 + T cells at tumor sites compared with that using syn-iMSC/CCL19. The antitumor effect of allo-iMSC/CCL19 therapy was not influenced by fingolimod, a sphingosine 1-phosphate receptor modulator, implying no involvement of draining lymph nodes in the priming of tumor-specific T cells.
Conclusion
These results suggest that allo-iMSC/CCL19 therapy exerts dramatic antitumor effects by promoting the infiltration of CD103 + IL-12-producing DCs and thereby priming tumor-specific CD8 + T cells at tumor sites. This local cell therapy could be a promising approach to anticancer therapy, particularly for overcoming dysfunction in the cancer-immunity cycle.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Immunology, Shimane University Faculty of Medicine Graduate School of Medicine, Izumo, Japan yiida@med.shimane-u.ac.jp.
- Immunology, Shimane University Faculty of Medicine Graduate School of Medicine, Izumo, Japan.
ORCID-Profile: Yuichi Iida
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Iida, Y., & Harada, M. (2024). Local cell therapy using CCL19-expressing allogeneic mesenchymal stem cells exerts robust antitumor effects by accumulating CD103 + IL-12-producing dendritic cells and priming CD8 + T cells without involving draining lymph nodes. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2024-009683
Vancouver
Iida Y, Harada M. Local cell therapy using CCL19-expressing allogeneic mesenchymal stem cells exerts robust antitumor effects by accumulating CD103 + IL-12-producing dendritic cells and priming CD8 + T cells without involving draining lymph nodes. Journal for ImmunoTherapy of Cancer. 2024. doi:10.1136/jitc-2024-009683
BibTeX
@article{Iida2024,
author = {Iida, Yuichi and Harada, Mamoru},
title = {Local cell therapy using CCL19-expressing allogeneic mesenchymal stem cells exerts robust antitumor effects by accumulating CD103 + IL-12-producing dendritic cells and priming CD8 + T cells without involving draining lymph nodes},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2024},
doi = {10.1136/jitc-2024-009683}
}
EUVIMED